News & Press - BioFlorida, Inc.

News & Press

Read about recent events, essential information and the latest community news.

Scientific Advancements
Monday, February 12, 2018 (0 Comments - view/add) FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic » FDA Approves SYMDEKO TM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in Peop...
Wednesday, February 7, 2018 (0 Comments - view/add) Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK » Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations...
Wednesday, February 7, 2018 (0 Comments - view/add) Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ing » Dyadic International, Inc. Announces Research and Development Collaboration To Produce An Active Ingredient in C1 02/07...
Wednesday, January 31, 2018 (0 Comments - view/add) Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Tr » Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophren...
Monday, January 29, 2018 (0 Comments - view/add) CTD Holdings Initiates Research Program to Explore Cyclodextrin Therapy for Alzheimer's Disease » CTD Holdings Initiates Research Program to Explore Cyclodextrin Therapy for Alzheimer's Disease ALACHUA, FL -- (Mark...
Wednesday, January 24, 2018 (0 Comments - view/add) Published Data Show Successful 24-Month Sacroiliac Joint Fusion and Pain Reduction with the SImmetry » Published Data Show Successful 24-Month Sacroiliac Joint Fusion and Pain Reduction with the SImmetry® System Stu...
Wednesday, January 24, 2018 (0 Comments - view/add) FSU psychologist receives $2M NIH grant to test nonmedication treatment for ADHD » FSU psychologist receives $2M NIH grant to test nonmedication treatment for ADHD By: Dave Heller \| Published: Jan...
Monday, January 8, 2018 (0 Comments - view/add) KemPharm Initiates Pivotal Efficacy Trial of KP415 » KemPharm Initiates Pivotal Efficacy Trial of KP415 'Classroom-style' Pivotal Efficacy Trial of ADHD...
Wednesday, January 3, 2018 (0 Comments - view/add) Area company Espero looks to hold trials for new drugs » Shared from the 2018-01-03 The Florida Times-Union eEdition Area company Espero looks to hold trials for new drugs...
Wednesday, January 3, 2018 (0 Comments - view/add) Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Tre » Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloi...
Tuesday, December 12, 2017 (0 Comments - view/add) TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negati » TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funde...
Sunday, December 10, 2017 (0 Comments - view/add) New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymph » New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients New ZU...
Wednesday, December 6, 2017 (0 Comments - view/add) CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM) » CTD Holdings Receives Rare Pediatric Disease Designation for Trappsol(R) Cyclo(TM) ALACHUA, FL -- 12/06/17 -- CTD...
Monday, December 4, 2017 (0 Comments - view/add) Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy » Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy Yescarta™ for Non-Hodgkin Lym...
Monday, November 27, 2017 (0 Comments - view/add) OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertroph » OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy Enlarg...
Monday, November 27, 2017 (0 Comments - view/add) Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of F » Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients w...
Thursday, November 16, 2017 (0 Comments - view/add) KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA » KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA All Clinical and Non-Clinical Pr...
Monday, November 6, 2017 (0 Comments - view/add) TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR » TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR BOCA RATON, Fla.--(BUSINESS WIRE)--N...
Thursday, November 2, 2017 (0 Comments - view/add) Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD) » Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD) Stati...
Tuesday, October 31, 2017 (0 Comments - view/add) Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with » Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthen...
Monday, October 30, 2017 (0 Comments - view/add) HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial » HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update Positive out...
Thursday, October 26, 2017 (0 Comments - view/add) M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program » M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program The ORIEN Avatar Program repres...
Wednesday, October 25, 2017 (0 Comments - view/add) RTI Surgical® Launches Fortilink®-C IBF System, the First 3D Printed Polymer-based Interbody Device » RTI Surgical ® Launches Fortilink ® -C IBF System, the First 3D Printed Polymer-based Interbody Device...
Wednesday, October 25, 2017 (0 Comments - view/add) New Study: 'Double Decker' Antibody Technology Fights Cancer » New Study: 'Double Decker' Antibody Technology Fights Cancer JUPITER, Fla. - Oct. 25, 2017 -- ...
Tuesday, October 24, 2017 (0 Comments - view/add) Minneamrita Announces FDA Clearance of Investigational New Drug (IND) Application and Initiation of » Minneamrita Announces FDA Clearance of Investigational New Drug (IND) Application and Initiation of a Phase I Clinical Tri...
Thursday, October 19, 2017 (0 Comments - view/add) Gene editing in the brain gets a major upgrade » Gene editing in the brain gets a major upgrade October 19, 2017 Scientists develop a new tool for precise g...
Wednesday, October 18, 2017 (0 Comments - view/add) FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients » FDA Approves Yescarta™, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients Moffitt Cancer...
Tuesday, October 17, 2017 (0 Comments - view/add) New Research Opens the Door to ‘Functional Cure’ for HIV » New Research Opens the Door to ‘Functional Cure’ for HIV JUPITER, FL – October 17, 2017 – In findings that open the do...
Tuesday, October 10, 2017 (0 Comments - view/add) Moffitt Researchers Discover New Targets for Approved Cancer Drug » For more information, contact: Lisa Chillura 813-745-1353 [email protected] ...
Monday, October 9, 2017 (0 Comments - view/add) Jupiter Medical Center Offers First Of Its Kind Procedure To Treat Adults with Severe Asthma » Emily Pantelides Jacobson Strategic Communications 904.477.2306/ [email protected] ...
Thursday, September 28, 2017 (0 Comments - view/add) CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatme » CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Dis...
Wednesday, September 27, 2017 (0 Comments - view/add) Lakewood-Amedex Inc. Reports Positive Top-Line Data from Randomized Controlled Phase 1/2a Trial of N » Lakewood-Amedex Inc. Reports Positive Top-Line Data from Randomized Controlled Phase 1/2a Trial of Nu-3 Antimicrobial in P...
Tuesday, September 19, 2017 (0 Comments - view/add) Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the U » Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the US Food and Drug Admini...
Monday, September 18, 2017 (0 Comments - view/add) CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study o » CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM...
Wednesday, September 6, 2017 (0 Comments - view/add) Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty » Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty MIAMI , Sept. 6, 2017 /PRNewswire/ --&n...
View "All News Items" »

Member Sign In

Forgot your password?

Don't have a profile?